Boston Scientific Appoints Joseph M. Fitzgerald as COO and Creates Three-Segment Business Structure

October 12, 2026—Boston Scientific Corporation announced the appointment of Joseph M. Fitzgerald to Executive Vice President and Chief Operating Officer (COO), effective January 1, 2027. He will oversee the company’s global operations, business units, and regions. Fitzgerald currently serves as Executive Vice President and Group President, Cardiovascular, Boston Scientific.

In conjunction with the appointment, Boston Scientific will establish three reportable segments in a structure designed to enable faster decision making and support strategic allocations of investments as the company continues to grow and expand its portfolio. This will take effect January 1, 2027.

The three segments are the following:

• Interventional Therapies will include the Interventional Cardiology, Vascular Therapies, and Interventional Oncology & Embolization businesses. The segment will include the Penumbra business after the anticipated close of the acquisition. The acquisition agreement was announced in January 2026. Lance Bates, Executive Vice President and President, Interventional Therapies, will lead the global Interventional Therapies segment.
• Rhythm Solutions will include Electrophysiology, Watchman, and Cardiac Rhythm Management & Diagnostics. Nick Spadea-Anello, Executive Vice President and President, Atrial Fibrillation Solutions, will lead the global Rhythm Solutions segment.
• MedSurg will include Endoscopy, Urology, and Neuromodulation. Stephen Morse, Senior Vice President and President, Asia Pacific, will serve as Executive Vice President and President, MedSurg and Asia Pacific.

The leaders of the three segments will report to Fitzgerald, stated Boston Scientific.